Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.48 USD | -1.20% | +10.22% | -22.01% |
04/06 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
15/05 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
End-of-day quotes
Sector Other Biotechnology & Medical Research
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
2.04Cr | - | - | - | |||
5.93TCr | - | |||||
4.09TCr | ||||||
4.02TCr | ||||||
2.87TCr | ||||||
2.66TCr |
- Stock Market
- Equities
- LUMO Stock
- Charts Lumos Pharma, Inc.
- Sector Chart